Highly Potent Drugs

Catalent to Invest $10 Million to Increase Isolator Capabilities at US and UK Sites

December 08, 2020

The company will expand its micronization abilities for highly potent drug compounds through this investment.

HPAPI Complexity Prompts New Delivery Mechanisms

December 03, 2020

Operator, caregiver, and patient safety are at the forefront when selecting the best options and dosage forms.

Formulating an ADC Development Solution

May 02, 2020

Many antibody-drug conjugate therapies are in the pipeline; however, only a handful have been approved. What are the bottlenecks?

Keeping Toxicity to a Minimum

March 02, 2020

Assays can provide a useful tool in determining the potential toxicity of drugs throughout the development cycle.

Best Practices in Handling HPAPIs

October 02, 2019

Establishing OEL data and ensuring appropriate engineering controls are crucial aspects of safe handling.

Majority of High-Containment CMO Facilities Located in 5EU and Switzerland, Notes GlobalData

August 15, 2019

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

In Safe Hands

August 02, 2019

Pharmaceutical Technology Europe

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.